Two-year Results of Intravitreal Ranibizumab Injections Using a Treat-and-extend Regimen for Macular Edema due to Branch Retinal Vein Occlusion

Mika Hosogi, Yusuke Shiode, Yuki Morizane, Shuhei Kimura, Mio Hosokawa, Shinichiro Doi, Shinji Toshima, Kosuke Takahashi, Atsushi Fujiwara, Fumio Shiraga

Research output: Contribution to journalArticle


We investigated the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 2-year results of 32 eyes of 32 patients who underwent TAE to treat ME due to BRVO. The patients whose treatment interval extended to ≥ 12 weeks were switched to a pro re nata regimen (PRN). For the patients whose treatment interval was <12 weeks, TAE was continued. At 2 years, 10 eyes had required no additional injections after the initial treatment period [recurrence(-) group], whereas the other 22 eyes required additional treatment [recurrence(+) group]. Among the recurrence(+) patients, 11 eyes (34.4% of total) were eventually switched from TAE to PRN; the other 11 eyes (34.4%) continued TAE for 2 years. Visual acuity and central retinal thickness were significantly improved in both the recurrence(+) and (-) groups, and there was no significant betweengroup difference in visual acuity at 2 years. Univariate analyses revealed significant differences in visual acuity (p=0.004), age (p=0.014), and vessel occlusion site (p=0.018) between these groups. Our results suggest that TAE may be effective for BRVO patients with lower visual acuity, older age, and occlusion of a major vein.

Original languageEnglish
Pages (from-to)517-522
Number of pages6
JournalActa medica Okayama
Issue number6
Publication statusPublished - Dec 1 2019



  • anti-vascular endothelial growth factor
  • branch retinal vein occlusion
  • macular edema
  • ranibizumab
  • treat-and-extend regimen

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this